Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small ...
A team led by Spaniard David Lagares is searching for a treatment for pulmonary fibrosis and other ailments associated with ...
GeoVax believes Gedeptin’s unique mechanism of localized tumor destruction combined with immune activation positions the program within a growing area of oncology focus: therapies designed to overcome ...
New research reveals PD-1 inhibitors may compromise the blood-brain barrier, influencing cancer treatment outcomes and brain ...
Engineered nanoparticles can improve cancer immunotherapy by delivering drugs, antigens, and genetic payloads with greater ...
Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering ...
Immune checkpoint inhibition disrupts receptor–ligand checkpoint signaling that restrains immunity, thereby enabling T-cell–mediated cancer-cell killing while increasing risk of autoimmune-like ...
A USC study finds immunotherapy increases PAD risk by 60%. Experts advise vascular monitoring to help prevent limb loss in ...
Researchers at Moffitt Cancer Center report encouraging early results from a phase 2 study examining whether immunotherapy ...
A new Phase I clinical trial provides proof of concept for a potential therapy for treatment-resistant cancers, particularly ...
Ultimately, Dr. Minn notes, success in immuno-oncology will be measured in multiple ways: Scientifically, by the depth of ...
Issued on behalf of GT Biopharma, Inc.After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results